|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bertolini G, Roz L, Perego P, et al:
Highly tumorigenic lung cancer CD133+ cells display
stem-like features and are spared by cisplatin treatment. Proc Natl
Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
|
|
3.
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Uchida N, Buck DW, He D, et al: Direct
isolation of human central nervous system stem cells. Proc Natl
Acad Sci USA. 97:14720–14725. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Rountree CB, Ding W, He L and Stiles B:
Expansion of CD133-expressing liver cancer stem cells in
liver-specific phosphatase and tensin homolog deleted on chromosome
10-deleted mice. Stem Cells. 27:290–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Van der Lugt NM, Domen J, Linders K, et
al: Posterior transformation, neurological abnormalities, and
severe hematopoietic defects in mice with a targeted deletion of
the bmi-1 protooncogene. Genes Dev. 8:757–769. 1994.
|
|
9.
|
Pirrotta V: Polycombing the genome: PcG,
trxG, and chromatin silencing. Cell. 93:333–336. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kranc KR, Bamforth SD, Braganca J, Norbury
C, van Lohuizen M and Bhattacharya S: Transcriptional coactivator
Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation
via Ink4a/ARF. Mol Cell Biol. 23:7658–7666. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Saito M, Handa K, Kiyono T, et al:
Immortalization of cementoblast progenitor cells with Bmi-1 and
TERT. J Bone Miner Res. 20:50–57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kim JH, Yoon SY, Kim CN, et al: The Bmi-1
oncoprotein is overexpressed in human colorectal cancer and
correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett.
203:217–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sasaki M, Ikeda H, Itatsu K, et al: The
overexpression of polycomb group proteins Bmi1 and EZH2 is
associated with the progression and aggressive biological behavior
of hepatocellular carcinoma. Lab Invest. 88:873–882. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Vrzalikova K, Skarda J, Ehrmann J, et al:
Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients:
a tissue microarray study. J Cancer Res Clin Oncol. 134:1037–1042.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Park IK, Qian D, Kiel M, et al: Bmi-1 is
required for maintenance of adult self-renewing haematopoietic stem
cells. Nature. 423:302–305. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Lessard J and Sauvageau G: Bmi-1
determines the proliferative capacity of normal and leukaemic stem
cells. Nature. 423:255–260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Liu S, Dontu G, Mantle ID, et al: Hedgehog
signaling and Bmi-1 regulate self-renewal of normal and malignant
human mammary stem cells. Cancer Res. 66:6063–6071. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Chiba T, Seki A, Aoki R, et al: Bmi1
promotes hepatic stem cell expansion and tumorigenicity in both
Ink4a/Arf-dependent and -independent manners in mice. Hepatology.
52:1111–1123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Glinsky GV: Stem cell origin of
death-from-cancer phenotypes of human prostate and breast cancers.
Stem Cell Rev. 3:79–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wang H, Pan K, Zhang HK, et al: Increased
polycomb-group oncogene Bmi-1 expression correlates with poor
prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol.
134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zhang Y, Li B, Ji ZZ and Zheng PS: Notch1
regulates the growth of human colon cancers. Cancer. 116:5207–5218.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tomuleasa C, Soritau O, Rus-Ciuca D, et
al: Isolation and characterization of hepatic cancer cells with
stem-like properties from hepatocellular carcinoma. J
Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
|
|
23.
|
Zhu Z, Hao X, Yan MX, et al: Cancer
stem/progenitor cells are highly enriched in CD133+CD44+ population
in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010.
|
|
24.
|
Leung C, Lingbeek M, Shakhova O, et al:
Bmi1 is essential for cerebellar development and is overexpressed
in human medulloblastomas. Nature. 428:337–341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vonlanthen S, Heighway J, Altermatt HJ, et
al: The bmi-1 oncoprotein is differentially expressed in non-small
cell lung cancer and correlates with INK4A-ARF locus expression. Br
J Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Kim JH, Yoon SY, Jeong SH, et al:
Overexpression of Bmi-1 oncoprotein correlates with axillary lymph
node metastases in invasive ductal breast cancer. Breast.
13:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Berezovska OP, Glinskii AB, Yang Z, Li XM,
Hoffman RM and Glinsky GV: Essential role for activation of the
Polycomb group (PcG) protein chromatin silencing pathway in
metastatic prostate cancer. Cell Cycle. 5:1886–1901. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Qin ZK, Yang JA, Ye YL, et al: Expression
of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer.
9:612009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chiba T, Miyagi S, Saraya A, et al: The
polycomb gene product BMI1 contributes to the maintenance of
tumor-initiating side population cells in hepatocellular carcinoma.
Cancer Res. 68:7742–7749. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Cui H, Hu B, Li T, et al: Bmi-1 is
essential for the tumorigenicity of neuroblastoma cells. Am J
Pathol. 170:1370–1378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Bruggeman SW, Hulsman D, Tanger E, et al:
Bmi1 controls tumor development in an Ink4a/Arf-independent manner
in a mouse model for glioma. Cancer Cell. 12:328–341. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Yu CC, Lo WL, Chen YW, et al: Bmi-1
regulates Snail expression and promotes metastasis ability in head
and neck squamous cancer-derived ALDH1 positive cells. J Oncol.
2011:pii:. 6092592011.PubMed/NCBI
|
|
34.
|
Park IK, Morrison SJ and Clarke MF: Bmi1,
stem cells, and senescence regulation. J Clin Invest. 113:175–179.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Dimri GP, Martinez JL, Jacobs JJ, et al:
The Bmi-1 oncogene induces telomerase activity and immortalizes
human mammary epithelial cells. Cancer Res. 62:4736–4745.
2002.PubMed/NCBI
|
|
36.
|
Jane EP, Premkumar DR and Pollack IF:
Coadministration of sorafenib with rottlerin potently inhibits cell
proliferation and migration in human malignant glioma cells. J
Pharmacol Exp Ther. 319:1070–1080. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Yu C, Friday BB, Lai JP, et al: Cytotoxic
synergy between the multikinase inhibitor sorafenib and the
proteasome inhibitor bortezomib in vitro: induction of apoptosis
through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer
Ther. 5:2378–2387. 2006. View Article : Google Scholar
|
